Audit: QRS - Taurine for Health & Longevity

Audit conducted on 12/08/2026 10:48 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: at-a-glance to Conclusion, protocol cells to Therapeutic Protocol, time cells to Practical Considerations, gates to Key Interactions & Contraindications, tiers to Expected Benefits / Potential Risks & Side Effects, table to Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER empty-state or hedged phrasing is carried into a populated QRS span; speculative tiers stay labelled “Speculative”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	All five avoid-populations remain in the STOP gate; all eight interactions remain in the CAUTION gate, matching the ER’s own split.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Nothing from ER Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates or the risk tiers.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or supplement brands in the QRS; the named drugs (lisinopril, losartan, amlodipine, hydrochlorothiazide, glipizide, glyburide, empagliflozin, ibuprofen, naproxen) all appear in ER line 294–302 for the same interactions.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS body.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, measured, evidence-first register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Numeric targets and dose ranges paired with plain-language framing in At-A-Glance and the protocol subs.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive constructions (“Pooled analyses found…”, “evening dosing suits…”), no imperatives.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommend”, or “advise” anywhere in the QRS body.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	All cells are statements of what the evidence shows or what protocols do.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns present.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	“estimated filtration rate” used instead of eGFR; remaining terms (HbA1c, hs-CRP, LDL-C) are biomarker names carried verbatim from the ER monitoring table.
2.8	Information is presented in a concise and very compact manner	🟢	Tier lines are semicolon-joined noun phrases; protocol subs are one sentence; gate items carry no rationale.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by scan — no “you”/”your”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal-range targets (e.g., hs-CRP below 0.8 mg/L, fasting insulin 2–5 µIU/mL) rather than conventional cut-offs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Thrice-daily dosing, weekly home blood-pressure logging and a ten-marker panel are presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Monitoring cadence and biomarker depth exceed general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance states effects are “largest where starting values are abnormal, minimal where normal” — the key discriminator for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the protocol label reads “Standard longevity-oriented dose”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Gastrointestinal intolerance”, “symptomatic hypotension”, “haematologic malignancy” used in the body; the plain-language wording is confined to At-A-Glance, where item 7.4 mandates it.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings byte-identical to [qrs_template] (lines 446, 492, 539, 618, 643, 790, 568, 583, 647–649 and the four tier labels).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Span-name diff against the template shows a complete match, with marker_#_* correctly expanded to marker_1..10_* and qualitative_item_# to qualitative_item_1..5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" spans, the CSS block, the override stylesheet link and the footer disclaimer are all untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Standard longevity-oriented dose”, “Split dosing”, “Best time of day”) and interaction labels (“Antihypertensive drugs”, “Glucose-lowering drugs”, “Lithium”, “Beta-alanine”, “Other interventions”) match the ER bold labels; only the em-dash rationale clauses required to be stripped by 9.4 are removed.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names and protocol labels are ER-verbatim; the time-to-effect labels are the ER’s own subjects from its Time to effect bullet (blood pressure / glucose and lipids / acute performance), which the ER does not itself present as bold labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s ⚠️ Conflicted markers were correctly dropped. Tiering is carried by CSS palettes and bold tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than transcribed: benefit and risk tiers reduced to bare noun phrases, gate items stripped of rationale, protocol subs cut to one sentence, monitoring “Why” cells to a short clause.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- line 3, closing --- line 13; the preamble text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; none of its values are repeated in the header, body or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: taurine_2026-0812-0835_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: 2026-0812-1028.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All nine values clean; git_user and git_issue unquoted and trimmed.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Taurine for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Taurine for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/12/2026, matching qrs_creation_date: 2026-0812-1028.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block (lines 415–428) is identical to the template apart from the four variable spans; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all four ER Conclusion paragraphs into what to expect, what is unproven, and where the hazards are.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Sources: ER line 457 (composition, modest improvements, baseline dependence, animal-only lifespan) and line 459 (safety record, additive hazards).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “blood sugar”, “blood fats”, “inflammation markers”, “sulfur compound”; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Only the generic “Controlled human trials”.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items map to the ER “Populations who should avoid Taurine” list (lines 312–316).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-populations present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Five <li> elements inside the span (lines 571–579).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationale “pending clarification of the 2025 tumour-niche findings” and “obtainable from food” are stripped; no dash-clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The 30 mL/min/1.73 m² threshold and dialysis, the 200 mg threshold, the AML severity class, the 100 mmHg threshold and the 400 mg supplemental threshold are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its avoid-populations list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names five such populations and the section is correctly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the ER interaction bullets (lines 294–308).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets present; no overlap with the STOP gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight <li> elements inside the span (lines 586–608).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “(caution — additive hypotension)” / “(monitor — …)” tags and the whole second sentence of each ER bullet (protocol rationale) are stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example drug is retained (lisinopril, losartan, amlodipine, hydrochlorothiazide; glipizide, glyburide, empagliflozin; ibuprofen, naproxen) and every supplement in the additive-hypotension list; only the class-name expansions (“angiotensin-converting enzyme inhibitors such as …”) are trimmed.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight such interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to ER Therapeutic Protocol bullets at lines 338, 346 and 348.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, dosing frequency and timing — the three decisions required to execute, chosen ahead of the population-specific protocols (heart failure, pre-exercise) and the non-actionable genetic/sex/age considerations.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies eleven protocol bullets; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	“1.5–3 g daily” (ER line 338), “Twice or thrice daily” (ER line 346), “With meals” (ER line 348), each with an ER-derived sub.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Blood pressure 2–4 weeks, glucose and lipids 8+ weeks, acute performance ~1 hour — the three windows in the ER’s Time to effect bullet (line 388).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Blood pressure and glycaemic/lipid endpoints are ER High-tier benefits, acute exercise performance is Medium-tier, and they appear in that order.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct windows; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated; the three subs are near-verbatim from ER line 388.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten benefit headings from ER lines 146–214 are represented in their original tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 541–561).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare semicolon-separated noun phrases; none of the ER’s Magnitude: figures (−4.0 mmHg, HbA1c −0.21%, g = 0.25, LVEF +4.98) are carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefit tier; the ER’s ⚠️ Conflicted markers on inflammatory markers, lifespan and cognition are also dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have ER items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven risk headings from ER lines 234–278 are represented in their original tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 620–637).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare noun phrases; the ER’s magnitude figures (about 4 mmHg, 5.9 mg/dL, 200 mg threshold) and mechanism sentences are absent.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk tier; the ER’s parenthetical gloss “(upper abdominal discomfort and bloating)” on dyspepsia and the ⚠️ Conflicted marker are dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers have ER items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows map one-to-one onto the ER Monitoring Protocol & Defining Success biomarker table (lines 416–427).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarkers present in ER order, with targets and “Why” text carried over: blood pressure, fasting glucose, HbA1c, fasting insulin, triglycerides, LDL-C, hs-CRP, ALT and AST, creatinine with estimated filtration rate, plasma taurine.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 781–784 condense ER line 414: weekly for four weeks then monthly, panels at 12 weeks then every 6–12 months, kidney function annually.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the ER’s “Qualitative markers worth tracking” list (lines 431–435).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Five of five present and in ER order: lightheadedness on standing, perceived exertion and time to exhaustion, upper abdominal discomfort, sleep latency and subjective calm, afternoon energy stability.

Issues 12/08/2026 10:48

Pass rate 100.00%. No issues found.

Issues 12/08/2026 10:41

1. 1.3 — Safety claim dropped its dose qualifier: [at_a_glance] (line 437) reads “Safety is unusually good”, while the ER Conclusion (line 459) reads “The safety record is unusually good at the doses studied”; removing the bound turns a dose-limited finding into an unqualified one.

Fixes 12/08/2026 10:41

1. 1.3 — Safety claim dose qualifier restored: [at_a_glance] now reads “Safety is unusually good at the doses studied”, matching the ER Conclusion; “largest where starting values are abnormal and minimal where they are normal” was tightened to “largest where starting values are abnormal, minimal where normal” to keep the block within the 60-word budget (now 59 words).

Issues 12/08/2026 10:35

1. 9.5 — Parenthetical example drugs dropped: Every parenthetical example drug from the ER’s interaction bullets is dropped entirely rather than trimmed — ER line 294 “ACE inhibitors (… lisinopril), ARBs (… losartan), calcium channel blockers (amlodipine) and diuretics (hydrochlorothiazide)” appears as “ACE inhibitors, ARBs, calcium channel blockers, diuretics” (QRS lines 587-588), ER line 296 “sulfonylureas (glipizide, glyburide) and SGLT2 inhibitors (… empagliflozin)” appears as “sulfonylureas, SGLT2 inhibitors” (QRS line 591), and ER line 304 “dietary nitrate (beetroot)” appears as “dietary nitrate” (QRS line 600).

Fixes 12/08/2026 10:35

1. 9.5 — Parenthetical example drugs restored: Re-added the ER’s parenthetical drug examples to the Key Interactions items — “ACE inhibitors (lisinopril), ARBs (losartan), calcium channel blockers (amlodipine), diuretics (hydrochlorothiazide)”, “sulfonylureas (glipizide, glyburide), SGLT2 inhibitors (empagliflozin)”, and “dietary nitrate (beetroot)”.